Investors
Information Disclosure
-
NEXT DAY DISCLOSURE RETURN2025.04.08
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF "TQB6411 (EGFR/C-MET BISPECIFIC ADC)"ACCEPTED BY CDE2025.04.03
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF "TQB2101 (ROR1 ADC)" APPROVED BY NMPA2025.04.03
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 20252025.04.01
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR FIRST-LINE TREATMENT OF HR-POSITIVE AND HER2-NEGATIVE ADVANCED BREAST CANCER2025.03.24
-
FINAL DIVIDEND FOR 20242025.03.20
-
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 20242025.03.20
-
VOLUNTARY ANNOUNCEMENT - RESULTS FROM PHASE IB/IIA CLINICAL STUDY OF FIRST-IN-CLASS JAK/ROCK INHIBITOR "ROVADICITINIB" PUBLISHED IN BLOOD2025.03.10